Morgan Stanley analyst Terence Flynn maintained a Sell rating on Bristol Myers (BMY – Research Report) today and set a price target of $62.00. The company’s shares opened today at $73.21.
Flynn covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Johnson & Johnson, and Revance Therapeutics. According to TipRanks, Flynn has an average return of 10.7% and a 60.74% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Bristol Myers with a $80.00 average price target.
See the top stocks recommended by analysts >>
The company has a one-year high of $80.80 and a one-year low of $61.06. Currently, Bristol Myers has an average volume of 8.99M.
Based on the recent corporate insider activity of 33 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BMY in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Founded in 1933, New York-based Bristol-Myers Squibb Co. is a global pharmaceutical company, which engages in the development, licensing, manufacturing, distribution, and sale of biopharmaceutical products in several therapeutic areas. These include cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders.
Read More on BMY:
- Pharma Earnings: Q4 Hits and Misses in a Post-COVID-19 World
- Exscientia announces 1st- in-human trial for Bristol-Myers in-licensed EXS4318
- Bristol-Myers sees FY23 adjusted EPS $7.95-$8.25, consensus $8.00
- Bristol-Myers reports Q4 adjusted EPS $1.82, consensus $1.72
- Notable companies reporting before tomorrow’s open
